Cognition Therapeutics Files 8-K
Ticker: CGTX · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1455365
| Field | Detail |
|---|---|
| Company | Cognition Therapeutics INC (CGTX) |
| Form Type | 8-K |
| Filed Date | Feb 26, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: COGT
TL;DR
COGT filed an 8-K on Feb 26, 2025. Details on events/financials TBD.
AI Summary
Cognition Therapeutics, Inc. filed an 8-K on February 26, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This 8-K filing indicates that Cognition Therapeutics, Inc. has made a regulatory submission, but the specific details of the events or financial statements are not elaborated in the provided text.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, and the provided text lacks specific material information that would indicate high risk.
Key Players & Entities
- Cognition Therapeutics, Inc. (company) — Registrant
- February 26, 2025 (date) — Date of earliest event reported
FAQ
What specific events are being reported in this 8-K filing?
The provided text for the 8-K filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items, but does not detail the specific nature of these events.
What is the principal executive office address for Cognition Therapeutics, Inc.?
The principal executive offices are located at 2500 Westchester Ave., Purchase, NY 10577.
When was Cognition Therapeutics, Inc. incorporated or organized?
The company was incorporated or organized in Delaware.
What is the SEC file number for Cognition Therapeutics, Inc.?
The SEC file number is 001-40886.
What is the fiscal year end for Cognition Therapeutics, Inc.?
The fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding COGNITION THERAPEUTICS INC (CGTX).